Cohn S M
Department of Surgery, University of Miami School of Medicine, FL 33101, USA.
Ann Med. 1997 Oct;29(5):371-6. doi: 10.3109/07853899708999364.
Haemoglobin-based red cell substitutes have recently passed a myriad of safety studies and are now undergoing efficacy evaluation. There are numerous potential benefits with use of these solutions: they are readily available and have a long shelf-life; do not require typing and cross-matching; are free of viral or bacterial contamination; lack the immunosuppressive effects of blood; and have a much lower viscosity than blood. One-third of the 10 million units of blood transfused in the United States each year is utilized in the emergency setting. Therefore, a safe, effective substitute for blood should have significant impact upon the way we resuscitate bleeding patients. In this article, the current status of the various haemoglobin-based red cell substitutes is reviewed.
基于血红蛋白的红细胞替代物最近通过了大量安全性研究,目前正在进行疗效评估。使用这些溶液有许多潜在益处:它们易于获得且保质期长;不需要血型鉴定和交叉配血;无病毒或细菌污染;没有血液的免疫抑制作用;并且粘度比血液低得多。在美国,每年输注的1000万单位血液中有三分之一用于紧急情况。因此,一种安全、有效的血液替代物应该会对我们抢救出血患者的方式产生重大影响。本文综述了各种基于血红蛋白的红细胞替代物的现状。